Evusheld, the only COVID-19 preexposure prophylaxis treatment with emergency use authorization, may not be effective against subvariant XBB.1.5, which makes up nearly 3 in 10 cases, the FDA said Jan. 6.
Read the full post on Becker's Hospital Review - Healthcare News